Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1649 1654 1675 1797
This examiner grants 51% of resolved cases
Jennifer Ann Benavides serves as an examiner in Tech Center 1700, working within Art Unit 1649. The examiner has a record of 121 resolved cases, providing a dataset for analysis. The allowance rate is 51.2 percent, indicating the frequency with which applications reach a grant. This 51.2 percent rate serves as the primary baseline for assessing prosecution risk on this docket. The 121 resolved cases establish the current statistical record for this examiner.
The interview lift is 47.0 percent, which is a high value compared to the baseline. This 47.0 percent lift suggests that conducting an interview is an effective strategy for improving the chances of an allowance. When compared to the 51.2 percent allowance rate, the benefit of direct engagement is clear. The median days to allowance is 1182, representing the typical timeframe for applications that successfully navigate the process. This 1182 median days to allowance helps set expectations for the overall timeline.
The data in Art Unit 1649 shows that the interview lift is 47.0 percent, highlighting the importance of oral advocacy. The 1182 median days to allowance provides a benchmark for pendency in Tech Center 1700. The 51.2 percent allowance rate remains a key metric for evaluating the likelihood of a grant. These figures provide a data-driven basis for a proactive prosecution strategy before this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18271584 | ANTICANCER COMPOUNDS AND USES THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18278797 | Highly Potent M-CENK Cells And Methods | Non-Final OA | ImmunityBio, Inc. |
| 17779499 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18509136 | ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18637337 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Non-Final OA | Avidity Biosciences, Inc. |
| 17762354 | NK ENGAGER COMPOUNDS THAT BIND VIRAL ANTIGENS AND METHODS OF USE | Non-Final OA | Regents of the University of Minnesota |
| 18672871 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Non-Final OA | Novartis AG |
| 18454457 | ANTIBODIES TO PMEL17 AND CONJUGATES THEREOF | Non-Final OA | Novartis AG |
| 18383398 | METHODS OF IMPROVING NEURODEGENERATIVE DISORDERS BY TARGETED DELIVERY OF THERAPEUTIC AGENTS | Non-Final OA | West Virginia University Board of Governors on behalf of West Virginia University |
| 16624422 | CAPTURE OF CIRCULATING TUMOR CELLS USING CARBON NANOTUBE SPONGES | Final Rejection | UNIVERSITY OF DELAWARE |
| 17776556 | Combination Therapy Based on PD-1 Signaling Inhibitors | Non-Final OA | Kyoto University |
| 18554184 | COMBINATION THERAPY WITH DEXAMETHASONE AND TUMOR-SPECIFIC T CELL ENGAGING MULTI-SPECIFIC ANTIBODIES FOR TREATING CANCER | Non-Final OA | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH |
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Final Rejection | Children's Medical Center Corporation |
| 17622634 | MODULATION OF DENDRITIC CELL FUNCTION BY THE PHOSPHOLIPID MESSENGER LPA | Final Rejection | Cornell University |
| 18020191 | IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS | Final Rejection | The U.S.A, as represented by the Secretary, Department of Health and Human Services |
| 18266443 | COMPOSITIONS AND USES OF CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED IMMUNE CELLS | Final Rejection | City of Hope |
| 18682827 | ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a | Non-Final OA | Nanjing GenScript Biotech Co., Ltd. |
| 18449591 | METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY | Non-Final OA | SEAGEN INC. |
| 18391559 | ANTIBODIES BINDING TO SARS-COV-2 VIRUS AND USES THEREOF | Final Rejection | ASSURE TECH. (HANGZHOU) CO., LTD. |
| 17693928 | TESTING METHODS FOR DETERMINATION OF T2R PHENOTYPE AND APPLICATIONS THEREOF | Non-Final OA | Phenomune, LLC |
| 18299453 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Final Rejection | Xygenyx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy